“borderline significant”

Effects of Different Interventions on CSHQ Scale Total Scores in Children with ASD The total CSHQ scale scores of the four groups were homogeneous in the pre-test scores (F (3,41) = 1.189, p = 0.326) and borderline significant in the posttest scores (F (3,41) = 2.794, p = 0.052).

Those treated with non–anti-TNF biologics had a lower IR of 1679.0 and a borderline significant reduction in risk (HR = 0.8, 95% CI = 0.7–1.0, p = 0.052).

Living in supported housing was associated with better adherence among aripiprazole users ( p = 0.033) and showed a borderline significant association among risperidone users (p = 0.052).

Though isoleucine and valine were not different, the difference in total BCAAs was borderline significant (p=0.052).

Clinical subgroup analysis of BMI and risk of recurrent myocardial infarction Age and Gender Stratification: As shown in Table 4 , in patients aged ≤60 years, BMI was associated with a borderline significant protective effect against recurrent myocardial infarction in males (HR = 0.969, 95% CI 0.939–1.000, P = 0.052), while in females, this effect was not statistically significant (HR = 0.954, 95% CI 0.878–1.037, P = 0.268).

IPW-adjusted pre-treatment PET/CT showed higher MTV 2.5 (HR 1.09, 95% CI: 1.02–1.17, p = 0.012) and TLG (HR 1.10, 95% CI: 1.00–1.20, p = 0.048) were significantly associated with worse PFS, and post-treatment MTV 2.5 was borderline significant (HR 1.16, 95% CI: 1.00–1.35, p = 0.052).

LAVi was only borderline significant in patients with AF (HR 1.03 [1.00–1.06], p = 0.052).

Results The prevalence of ESBL-E in admitted horses was 3% (5/161, 95% CI 1–7%); none of the tested factors remained statistically significant in multivariate analysis, although antimicrobial treatment within three months was borderline significant ( p = 0.052).

7%); however, the difference was only borderline significant ( p = 0.052).

Respiratory infections in the treatment (non-placebo) cohorts of the STRIVE ENVISION groups rose significantly from 21% of the treatment group at the start of PERSIST to 29% after 144 weeks of treatment ( p = 0.039—by paired χ 2 test of proportions in a single sample) while pulmonary exacerbations rose at the same timepoints from 38% to 46% (borderline significant: p = 0.052).

For IL-1β, the overall difference between groups was borderline significant (global unadjusted p = 0.052; age-adjusted p = 0.051), with a trend toward higher medians in periodontitis (5.1-fold vs. healthy, p = 0.067; 3.7-fold vs. gingivitis, p = 0.195; Fig. 2 b).

For gut ( Figure 3b ), the response was borderline significant on Day 180 ( p = 0.052) and significant on Day 365 ( p <0.001).

The mean difference in pre- and post-intervention scores was borderline significant, changing from 4.00±0.71 pre-intervention to 3.56±0.53 post-intervention (p=0.052) (Table 3 ).

We found that individuals with the rs1135519 CC genotypes had a significant increased risk of HCC than those with TT genotypes (adjusted OR=2.71, 95% CI=1.15-6.36, and P =0.022), while the rs9966765 CC genotypes showed a borderline significant association with increased risk of HCC when compared with the GG genotypes (adjusted OR=2.38, 95% CI=0.99-5.75, and P =0.052).

There was one borderline significant difference (F = 3.67 (1,1024), P = 0.052) for DINE fibre.

High-fat dairy remained borderline significant in the direct association with ucOC in another multivariate model with an adjustment for vitamin K, age, and sex (Standardized β = 0.06, P = 0.052 for high-fat dairy).

Therefore, analysis for mediation by methylation of V on lung function was deferred. Sensitivity analyses First, after controlling for time spent home, the main findings in Table 2 remained similar although the association between V and methylation of IL4 CpG −326 became borderline significant (RR [95% CI]: 0.81 [0.66-1.00]; p = 0.052 for IL4 CpG −326 and 0.81 [0.67-0.97]; p = 0.026 for IFNγ CpG −54 ).

We found a significant reduction in phosphorylation levels of GSK3α/β (53.4% reduction, P < 0.001), and a borderline significant reduction in CREB (34% reduction, P = 0.052) and mTOR phosphorylation (21.4% reduction, P = 0.062) (Fig. 5 B) after 48 h exposure to 10 μM SB747651A.

The effect of carbimazole was borderline significant compared to the control group ( p = 0.052), whereas the effect of L-thyroxine was highly significant ( p < 0.0001).

We found a significant influence of time on the levels of log PTH ( p = 0.007), 1,25(OH) 2 vitamin D ( p = 0.001), but only a borderline significant influence of time on log FGF23 ( p = 0.052).

NK cells continued to show an independent protective association (OR = 0.64, 95% CI 0.46–0.89, P = 0.007), while Treg was borderline significant ( P = 0.052); the remaining markers were not statistically significant after mutual adjustment (Fig. 4 ).

Unexpectedly, the results revealed that antiplatelet therapy use showed a borderline significant association with a lower hemoglobin decrease (Coef. = −6.53, p = 0.052, 95% CI [−13.11; 0.05]).

Crude TKR rates were 2.3% in the bisphosphonate group, 0.9% in the denosumab group, and 0.9% in the raloxifene group, with a borderline significant difference among the groups ( p = 0.052).

Efficacy information was prominent in cancer news in the order of colorectal, liver, cervical, skin, stomach, prostate, lung, breast, pancreatic, and thyroid cancers, and their mean differences were borderline significant, F ( df = 9) = 1.89, P = 0.052.

The relationship became borderline significant after adjusting for additional covariates in the final model (model 4: β=0.425, 95% CI= -0.004 to 0.854, p=0.052) ( Table 3 ).